MUMBAI, March 12 (Reuters) – Global drugmakers have had a
nauseous time in India’s $14 billion market. Prices have dropped
and valuable patents have been overruled as the authorities
strive to make medicines affordable for the 70 percent of people
living on less than $2 a day.
From a regulatory perspective, the government has “messed
up”, as one top industry consultant put it. But with 1.2 billion
people increasingly seeking both on- and off-prescription drugs,
the market is too big for firms to simply throw in the towel.
MUMBAI/LONDON (Reuters) – Indian drugmaker Ranbaxy Laboratories Ltd is in talks with at least two companies on sourcing ingredients for a generic version of AstraZeneca Plc’s heartburn drug Nexium, a source said, to ensure the pills can be sold in the United States.
The United States banned shipments from one of Ranbaxy’s plants in India following an inspection that found poor manufacturing practices, effectively barring India’s top drugmaker by revenue from selling drugs in the United States from its India plants.
LONDON (Reuters) – A U.S. biotech company pioneering tablets containing edible embedded microchips that can tell if patients have taken their medication is to establish its first international manufacturing site in Britain.
Privately held Proteus Digital Health, which is working with drugmakers including Novartis and Otsuka, said on Monday the new site would employ some 200 skilled staff and serve as a hub for the emerging digital medicine industry.